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OBJECTIVE — Dipeptidyl peptidase IV (DPP-IV) is not only important in -cell function but
also has proinflammatory actions. We aimed to investigate whether it could act as a link between
low-grade chronic inflammation and diabetes.
RESEARCHDESIGNANDMETHODS — Using a case-cohort design, we followed 546
middle-aged individuals who developed diabetes and 538 who did not over 9 years within the
Atherosclerosis Risk in Communities study.
RESULTS — In weighted analyses, the correlation between DPP-IV levels and anthropomet-
ric, inflammatory, or metabolic variables was minimal (Spearman correlations 0.11). Those
who developed diabetes had mean DPP-IV values similar to those who did not (P  0.18).
Individuals in the highest quartile of DPP-IV were not at greater risk of diabetes (hazard ratio
0.88 [95% CI 0.62–1.24]) in Cox proportional hazards models adjusting for age, sex, race, study
center, and multiple additional diabetes risk factors.
CONCLUSIONS — Fasting DPP-IV levels do not appear to predict incident diabetes.
Diabetes Care 33:1109–1111, 2010
T ype 2 diabetes is a leading cause ofmorbidity and mortality (1). Despitenumerous reports of inflammatory
markers that predict the development of
diabetes (2,3), the metabolic signaling
pathways linking inflammation to diabe-
tes are far from well understood. One pos-
sible link involves the enzyme dipeptidyl
peptidase IV (DPP-IV), a molecule with
multiple proinflammatory actions. Also
known as CD26, DPP-IV presents not
only as a circulating molecule but also as a
membrane-associated peptidase in nu-
merous tissues including subsets of leu-
kocytes. DPP-IV, as a T-cell surface
antigen, is involved in the production of T
helper 1 type cytokines (4,5). DPP-IV
knockout rodents show major alterations
in immune function (6). Because DPP-IV
is the major known inhibitor of incretins,
important stimulators of insulin secretion
and -cell mass (4), we hypothesized that
DPP-IV levels, possibly higher in the
chronic mild inflammatory state that pre-
cedes diabetes, could exert greater inhibi-
tion of -cell function in this setting.
DPP-IV activity was, in fact, found to be
higher in diabetes in one small cross-
sectional study (7), although this finding
has not been a consistent one (8,9), and
larger studies with incident diabetes are
lacking. The aim of our study was to ex-
plore this possible link by determining
whether fasting levels of DPP-IV in mid-
dle-age adults predict the development of
diabetes.
RESEARCH DESIGN AND
METHODS — The Atherosclerosis
Risk in Communities (ARIC) study re-
cruited a population-based cohort of
15,792 individuals aged 45– 64 years
from four U.S. communities between
1987 and 1989 and followed them with
three repeat visits over 9 years (10–12).
Here we analyze a case-cohort sample of
ARIC participants composed of 546 with
incident diabetes and 538 without diabe-
tes. Diabetes was defined on the basis of a
reported physician diagnosis, use of an-
tidiabetes medications, or a fasting glu-
cose value 7.0 mmol/l. Human subject
research review committees at the in-
volved institutions approved the study,
and all participants gave written informed
consent.
We analyzed DPP-IV levels at a cen-
tral laboratory in previously unthawed
plasma collected at the baseline examina-
tion and stored for 20 years at 70°C.
The plasma DPP-IV concentration was
measured in duplicate using a solid-phase
sandwich ELISA (R&D Systems, Minne-
apolis, MN) according to the manufactur-
er’s protocol and averaged. A reliability
coefficient of 0.87 and a coefficient of
variation of 8.9% were obtained for
DPP-IV when replicate pairs of samples
drawn at baseline from a subset of 38 sub-
jects were analyzed. Intra- and interassay
coefficient of variation values for DPP-IV
were 3.3 and 8.8%, respectively.
We used weighted Spearman correla-
tions to describe crude associations,
weighted ANCOVA to compute adjusted
DPP-IV means in diabetes case subjects
and nondiabetic subjects, and Cox pro-
portional hazards regressions to analyze
the risk of incident diabetes in those with
higher plasma DPP-IV levels. Statistical
analyses were performed using SAS (SAS
Institute, Cary, NC) and SUDAAN statis-
tical software packages, based on the case-
cohort sampling design. Additional
methodological details can be found in the
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supplementary data (available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1996/DC1).
RESULTS — Characteristics of case
subjects and nondiabetic subjects have
been reported previously (12). The range
for DDP-IV values found is in line with
the reference range for apparently healthy
individuals, as reported by R&D Systems
and as reviewed by Cordero et al. (13).
Spearman correlations, assessed in
the cohort random sample (n  631),
showed no association between DPP-IV and
anthropometric (BMI and waist-to-hip ra-
tio), inflammatory (C-reactive protein, in-
terleukin-6, fibrinogen, orosomucoid, and
sialic acid), or metabolic (adiponectin, lep-
tin, nonesterified fatty acids, triglycerides,
HDL cholesterol, and baseline fasting glu-
cose) variables or other participant charac-
teristics (systolic and diastolic blood
pressure). Small associations were found
between DPP-IV and white blood cell count
(r  0.09, P  0.02), serum creatinine
(r  0.11, P  0.01), and insulin levels (r 
0.08, P  0.04).
Individuals who developed diabetes
had DPP-IV mean values at baseline sim-
ilar to those of individuals who did not
develop diabetes: 381.5 ng/ml (95% CI
372.5–390.5) vs. 388.9 ng/ml (379.7–
398.1) when adjusted for age, sex, race,
and study center (P  0.25) and 377.3
ng/ml (363.2–391.5) vs. 389.5 ng/ml
(380.3–398.6) when additionally ad-
justed for BMI, waist-to-hip ratio, inflam-
mation score (10), adiponectin, leptin,
triglycerides, HDL cholesterol, hyperten-
sion, parental history of diabetes, insulin,
and glucose levels at baseline (P  0.18).
DPP-IV mean values were statistically
different between African Americans and
whites (421.9 ng/ml [95% CI 407.4 –
436.5] vs. 380.0 ng/ml [369.2–390.8] in
the minimally adjusted model and 429.8
ng/ml [410.0 – 449.6] vs. 378.2 ng/ml
[366.9–389.4] in the fully adjusted model,
P  0.01 for each comparison). Survival
analyses for highest (versus lowest) DPP-IV
quartile showed no greater risk of diabetes
(HR 0.88 [95% CI 0.62–1.24], P  0.46,
when minimally adjusted, and 0.90 [0.58–
1.40], P  0.64, when fully adjusted).
No statistically significant modifica-
tion of associations between DPP-IV and
incident diabetes was found in comparing
associations in men and women, African
Americans and whites, obese and nono-
bese participants, or current smokers and
nonsmokers or in those with a higher ver-
sus lower inflammation score (10) or hav-
ing impaired fasting glucose or not. Table
1 presents the HRs in sex and ethnicity
strata with minimal and full adjustment.
CONCLUSIONS — Limitations to
our study should be acknowledged: We
measured DDP-IV in a fasting state and
cannot exclude the possibility that post-
prandial levels predict incident diabetes.
Further, we measured DPP-IV levels, not
DPP-IV activity. However, we know of no
study suggesting a rapid change in
DPP-IV with food ingestion, and in
healthy individuals, 95% of serum
DPP-IV activity is associated with DPP-IV
protein levels (14). In sum, in what is to
our knowledge the first large, long-term
study with individuals with incident cases
of diabetes, we found little or no baseline
correlation between fasting DPP-IV levels
and biomarkers of mild, chronic inflamma-
tion and no association, even in minimally
adjusted models, between fasting DPP-IV
levels and incident disease. Thus, despite
the fact that DPP-IV, the major inhibitor of
incretins (15), has proinflammatory ac-
tions, fasting DPP-IV levels do not appear to
predict the development of diabetes. Fast-
ing DPP-IV is thus unlikely to be a link be-
tween inflammation and the development
of diabetes. African Americans present ad-
justed DPP-IV mean values 10% higher
than their white counterparts.
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